SKB410

Phase Ia (dose escalation phase) Primary objective: To evaluate the safety and tolerability of SKB410 in subjects with advanced solid tumors. Secondary objectives: To evaluate the pharmacokinetic characteristics of SKB410 in subjects with advanced solid tumors; To evaluate the immunogenicity of SKB410 in subjects with advanced solid tumors; To evaluate the preliminary efficacy of SKB410 in subjects with advanced solid tumors (efficacy indicators: ORR, DCR, DOR, PFS, OS). Phase Ib (dose expansion phase) Primary objective: To preliminarily evaluate the objective response rate (ORR) of the selected dose of SKB410 in subjects with specific tumor types. Secondary objectives: To evaluate the safety and tolerability of the selected dose of SKB410 in subjects with specific tumor types; To preliminarily evaluate the efficacy of the selected dose of SKB410 in subjects with specific tumor types (efficacy indicators: DCR, DOR, PFS, OS); To evaluate the pharmacokinetic characteristics of SKB410 in subjects with specific tumor types; To evaluate the immunogenicity of SKB410 in subjects with specific tumor types.